Nearly 20 years ago, Charles A. Janeway, Jr. proposed the existence of an innate immune recognition mechanism that would identify conserved molecular structures expressed by microbes but not by eukaryotic hosts (Janeway, 1989) . Such a recognition mechanism (termed pattern recognition) was hypothesized to enable a eukaryotic host to reliably detect a microbial infection. This hypothesis has since been confirmed with the identification of several families of pattern recognition receptors, of which Toll-like receptors (TLRs) are the best characterized. All TLRs have a common domain organization, with an extracellular recognition domain consisting of leucine-rich repeats (LRRs), a single transmembrane domain, and an intracellular Toll/IL-1 receptor homology (TIR) signaling domain. TLR4 signaling is activated in response to bacterial lipopolysaccharide (LPS), the bacterial component responsible for endotoxic shock, whereas TLR2 signaling is activated in response to a variety of both bacterial and fungal cell wall components. A variety of LRR domain-containing proteins have been crystallized, revealing that these domains form horseshoe-like structures with parallel β strands forming the concave face and the convex surface composed of loops and a type of secondary structure known as 3 10 helices. The first structure of an LRR protein bound to its ligand-RNase inhibitor bound to RNase-revealed that the protein-protein interactions occur at the concave face of the LRR horseshoe structure (Kobe and Deisenhofer, 1995) . However, although the microbial ligands that activate TLRs are well known, the mechanism of TLR-mediated pattern recognition has remained a mystery largely because TLRs have been refractory to crystallographic analysis.
In a recent issue of Cell, Kim, Lee, and their colleagues report a clever new approach (termed the hybrid LRR technique) to crystallize TLRs. They describe crystal structures of the TLR4 extracellular domain in complex with MD-2, a soluble protein required for TLR4 signaling. They also present the structure of TLR4 in complex with MD-2 bound to eritoran, an analog of LPS that antagonizes TLR4 signaling. Due to this ability to antagonize TLR4 signaling, eritoran is currently in phase III clinical trials for the treatment of severe sepsis. Meanwhile, in this issue, Jin, Lee, and their colleagues (Jin et al., 2007) apply their method to crystallize the complex of TLR1 and TLR2 extracellular domains bound to a synthetic lipopeptide agonist Pam 3 CSK 4 .
Their elegant strategy involves the use of hybrid proteins consisting of portions of mouse or human TLR-LRR domains fused to LRRs from variable lymphocyte receptor (VLR) proteins found in hagfish. Using a series of overlapping fusion constructs, Kim et al. were able to generate the first structure of the TLR4-LRR domain. One novel feature of the TLR4-LRR domain is that it possesses a three-domain architecture in which the entire LRR can be subdivided into N-terminal, central, and C-terminal subdomains, each with characteristic structural features and with sharp demarcations at the subdomain junctions. Kim et al. (2007) also discovered that some TLR-VLR hybrids could bind to MD-2 or to MD-2 in complex with eritoran and could also Toll-like receptors (TLRs) are membrane-bound sensors that detect and respond to microbial infection. Two studies in Cell, one in this issue, reveal how TLRs recognize their ligands. Kim et al. (2007) recently reported the structure of TLR4 bound to the accessory protein MD-2 and its antagonist, the drug eritoran. In this issue, Jin et al. (2007) describe the crystal structure of a complex between TLR1, TLR2, and a lipopeptide ligand.
be crystallized. Together, these crystal structures provide a key advance in our understanding of how TLRs recognize their ligands. Intriguingly, TLR4 binds to MD-2 and to MD-2-eritoran at the concave face of the LRR, at the junction of the N-terminal and central LRRs. This is in contrast to predictions of ligand binding from previous structures of the TLR3-LRR domain (Bell et al., 2005; Choe et al., 2005) , as well as from the structure of TLR1-TLR2-Pam 3 CSK 4 (Jin et al., 2007) (Figure 1) .
One of the more striking aspects of the crystal structure of the complete TLR4-MD-2-eritoran complex is that there are no direct contacts between eritoran and TLR4. Rather, the four acyl groups of eritoran occupy nearly 90% of the available space within the hydrophobic pocket in MD-2, whereas the phosphate groups of the diglucosamine backbone make ionic contacts with positively charged residues at the surface of the pocket. Indeed, this is very similar to the recent structure of MD-2 in complex with the LPS precursor lipid IVa (Ohto et al., 2007) . In this structure, lipid IVa also occupies virtually the entire volume of the deep hydrophobic pocket in MD-2, with the diglucosamine moieties exposed to solvent at the surface of the pocket. In contrast to eritoran and lipid IVa, which are TLR4 antagonists, most canonical agonist LPS structures (such as E. coli or Salmonella LPS) contain six acyl chains. It will be important to understand what structural changes occur in MD-2 in order to accommodate the increased size of agonist LPS. This is particularly interesting because the eritoran-MD-2 complex fails to induce TLR4 dimerization, whereas MD-2 bound to LPS does. This suggests that as a general rule, TLR agonists will induce TLR dimerization, whereas antagonists are likely to interfere with dimerization. Indeed, analyses by others (Kobayashi et al., 2006) as well as Kim et al. (2007) demonstrate that residues of MD-2 not involved in direct contact with either LPS or TLR4 play a key role in homodimerization of the TLR4-MD-2 complex in the presence of LPS. Kim et al. thus propose a model in which the interaction of LPS with MD-2 bound to one TLR4 protein results in allosteric changes in MD-2 that promote the interaction of MD-2 with the central or C-terminal domain of a second TLR4 protein.
The second study by Lee and colleagues (Jin et al., 2007) indicates that like TLR4, both TLR1 and TLR2 are structurally "atypical" members of the LRR superfamily, as their LRR domains can be subdivided into N-terminal, central, and C-terminal subdomains, each of which has a characteristic β sheet conformation. However, in contrast to MD-2 binding of TLR4, binding of triacylated lipopeptide to TLR2 occurs in a lipid-binding pocket that is formed at the convex face of the junction between the central and C-terminal LRR domains. This pocket accommodates two of the acyl chains of the synthetic TLR agonist, Pam 3 CSK 4 , whereas a similar lipid-binding pocket in TLR1-also at the junction between the central and C-terminal LRR domains-accommodates the third acyl chain. This structure explains the requirement for TLR2-TLR1 heterodimerization for the response to triacylated lipopeptides. Despite the lack of a third acyl group, diacylated Pam 2 CSK 4 interacts with the lipid-binding pocket of TLR2 in virtually the same fashion as Pam 3 CSK 4 . Interestingly, modeling of TLR6 by Jin et al. suggested that it lacks the lipid-binding pocket of TLR1. It will therefore be particularly enlightening to understand how TLR2-TLR6 dimerization occurs. TLR6 may interact directly with the peptide portion of diacylated lipopeptides, or with the glycerophosphate moiety of lipoteichoic acid (LTA), which are exposed to solvent and may therefore form ionic contacts with residues from TLR6.
A particularly surprising aspect of the two sets of findings by Lee and colleagues is that the mode of ligand recognition by TLR4-MD-2 and TLR1/TLR2 is completely different in terms of the site of ligand binding and the requirement for accessory proteins ( Figure  1 ). It has been puzzling how TLRs can detect multiple ligands that are struc- (Jin et al., 2007) . A single Pam 3 CSK 4 molecule is sufficient to induce heterodimerization due to the presence of three acyl chains, two of which bind TLR2 in a hydrophobic pocket at the junction of the central and C-terminal LRR subdomains; the third acyl chain binds a hydrophobic pocket in TLR1. (Right) In contrast, binding of TLR4 to MD-2 occurs at the convex face of the TLR4 extracellular domain, at the junction of central and N-terminal LRR subdomains . LPS-induced TLR4 dimerization is presumed to require two molecules of MD-2 each bound to an individual LPS molecule, such that LPS-induced structural changes in MD-2 enable each MD-2 molecule to make simultaneous contacts with both TLR4-LRR domains. The LPS analog eritoran does not make direct contact with TLR4. It is presumed, therefore, that LPS also does not contact TLR4 directly, but rather induces dimerization through the interactions of MD-2 with TLR4. turally unrelated to each other. One possibility suggested by these studies is that protein ligands (such as flagellin or porins) may bind their respective TLRs in a manner exemplified by MD-2, that is, in the concave surface of the TLR ectodomains. The nonprotein TLR ligands (including nucleic acid ligands), on the other hand, are likely to bind in the manner exemplified by the Pam 3 CSK 4 , that is, at the convex face of a pair of ectodomains.
Crystallization of TLRs in complex with their ligands has eluded the field of TLR biology for nearly a decade. The papers by Kim et al. and Jin et al. reveal a new approach that is likely to be applicable to the crystallization of additional TLRs. TLR4-MD-2 still remains to be cocrystallized with its agonist ligand, LPS; however, the cocrystal of TLR2-TLR1-Pam 3 CSK 4 reveals the first structural basis for ligand-induced receptor dimerization of TLRs. These two papers together also provide a structural basis for the possible generation of hybrid TLRs that may possess new ligand binding and response properties.
Initial evidence for the involvement of the DISC1 (Disrupted-in-Schizophrenia 1) gene in schizophrenia was based primarily on a large Scottish pedigree where the gene was disrupted by a chromosomal translocation. Several other linkage and association studies also connect DISC1 to schizophrenia and to other psychotic and affective disorders (Mackie et al., 2007) . Thus understanding the role of the DISC1 gene product could reveal insights into the pathophysiology of psychiatric illness. Analysis of DISC1 function supports a role in regulating neuronal migration and structural plasticity. DISC1 expression is highest during the neurogenic period of development and in neurogenic regions in the adult rodent brain. Although much work has focused on the involvement of DISC1 in neurogenesis during development, new work by Duan et al. (2007) reveals an unexpected role for DISC1 in the maturation of neurons born during adulthood.
During embryonic development DISC1 regulates neuronal migration and structural plasticity, apparently through its involvement in microtubule dynamics (Kamiya et al., 2005) . DISC1 interacts with members of the dynein microtubule motor complex, including LIS1 and NudEL, in a pathway regulated by Reelin (another protein implicated in schizophrenia). Both LIS1 and NudEL are involved in the control of microtubule assembly by the centrosome and hence neuritic growth and neuronal migration (Shu et al., 2004) . Moreover, mutations in LIS1 are linked to lissencephaly, a disease of aberrant neuronal migration during cortical neurogenesis. Thus, mutations in several genes that encode proteins of the dynein complex are associated with neurodevelopmental diseases, including schizophrenia.
Expression of C terminally truncated DISC1 in cell culture, in attempts to mimic the Scottish pedigree translocation, results in dissociation of the dyenin complex from the centrosome, suggesting a loss-of-function phenotype (Ross et al., 2006) . Furthermore, decreasing DISC1 expression in utero by RNA interference (RNAi) greatly limits the radial migration of neuroblasts toward their cortical destinations (Kamiya et al., 2005) . In addition, expression of truncated
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